On July 13, 2022, ICER released its draft evidence report, “Medications for Obesity Management.” This document provides a framework for considering what aspects of the four medical treatments ICER included in its review are important to patients and their families, and how to consider presenting those perspectives. This guide specifically provides insights about how to read and respond to ICER’s draft evidence report, as well as how to request a slot to make comments during ICER’s public meeting.
Categories
- Access
- California
- Comment Letters
- Copay Accumulators
- Copay Assistance
- COVID-19
- Drug Costs
- FDA
- Featured
- Featured Action
- Federal Issues
- Health Insurance
- Health Policy
- ICER
- Illinois
- Issues
- Letters Submitted
- Letters Supported
- Massachusetts
- Medicaid
- Medicare
- Medicare Part D
- News
- Op-Ed
- Out of Pocket Costs
- Pharmacy Benefit Managers
- Podcast
- Prescription Drugs
- Press Releases
- Public Statement
- QALY
- State Issues
- Statements
- Step Therapy
- Surprise Billing
- Terry's Hot Take
- Uncategorized
- Value Based Insurance Design
- Value Frameworks
- Virtual Advocacy Chat
Tags
21st Century Cures Act
340B
Access to Care
Advocacy
Alzheimer's
Biden Administration
biosimilars
Cancer
cms
Copay Accumulators
copay assistance
COVID-19 Vaccine
drug costs
Drug Manufacturing
Drug Pricing
drug rebate
fail first
FDA
H.R.3
Healthcare Inequities
Health Insurance
hospital bills
HR 3708
hsa
ICER
Insurance design
Joe Biden
Lupus
medicare Part B
medicare part D
Nonmedical Switching
open enrollment
Out of Pocket Costs
PBM
PBMs
pharmacy benefit managers
Price Transparency
Prior Authorization
QALY
Rare Disease
Right to Repair
Step Therapy
Telehealth
transparency
Value Framework
Recent Posts
- Patients Rising Now Releases “What You Don’t Know About the Reconciliation Bill”
- PRN Sends Letter to HHS Calling for Increased Patient Protection in Nuclear Medicine
- Making Medicaid Postpartum Coverage Extension a Priority
- Wilcox Statement on Medicare Negotiation in Reconciliation
- REFUND Act: Claiming a Discarded Drug Rebate from Pharma